Viridian Therapeutics (NASDAQ:VRDN) versus CannLabs (OTCMKTS:CANL) Critical Survey

Viridian Therapeutics (NASDAQ:VRDN) and CannLabs (OTCMKTS:CANL) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, analyst recommendations, earnings, risk and profitability.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Viridian Therapeutics and CannLabs, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viridian Therapeutics	0	2	9	0	2.82
CannLabs	0	0	0	0	0.00

Viridian Therapeutics presently has a consensus price target of $36.33, suggesting a potential upside of 103.55%. Given Viridian Therapeutics’ stronger consensus rating and higher possible upside, analysts clearly believe Viridian Therapeutics is more favorable than CannLabs.

Risk & Volatility

Viridian Therapeutics has a beta of 1.04, suggesting that its stock price is 4% more volatile than the S&P 500. Comparatively, CannLabs has a beta of 1.5, suggesting that its stock price is 50% more volatile than the S&P 500.

Valuation and Earnings

This table compares Viridian Therapeutics and CannLabs”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viridian Therapeutics	$302,000.00	4,681.96	-$237.73 million	($4.31)	-4.14
CannLabs	N/A	N/A	N/A	N/A	N/A

CannLabs has lower revenue, but higher earnings than Viridian Therapeutics.

Profitability

This table compares Viridian Therapeutics and CannLabs’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Viridian Therapeutics	-85,127.16%	-70.12%	-41.49%
CannLabs	N/A	N/A	N/A

About Viridian Therapeutics

Viridian Therapeutics, Inc., a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED. It also provides VRDN-006 a preclinical program for autoimmune disease. In addition, the company offers VRDN-006 and VRDN-008 a preclinical program for autoimmune disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021.Viridian Therapeutics, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.

About CannLabs

CannLabs, Inc. provides cannabis testing laboratory services in the United States. Its testing services include potency testing, residual solvent analysis, microbiological testing, pesticide testing, heavy metals testing, nutrient analysis, terpenes analysis, shelf-life/stability studies, gene expression testing, and genotyping/phenotyping testing. The company also offers data/analytics and consulting, as well as education services. CannLabs, Inc. was incorporated in 2010 and is based in Denver, Colorado.